Mabaloxavir Intermediate | GMP-Certified API Intermediate for Anti-Influenza Drug Synthesis & Antiviral Research?

?? ?Product Overview?

Mabaloxavir Intermediate is a ?high-purity chemical building block? critical for synthesizing ?Baloxavir Marboxil?, a next-generation anti-influenza API targeting viral cap-dependent endonuclease?13. Designed for pharmaceutical manufacturers and research labs, this intermediate enables scalable production of antiviral drugs with ?>99% HPLC purity? and ?full regulatory compliance??25.

?? ?Key Features?

• ?GMP-Certified?

  : Manufactured in ISO 9001 facilities with ICH Q7 compliance for global regulatory acceptance?25.

• ?High Stability?

  : 24-month shelf life under controlled storage (2-8°C in nitrogen-sealed amber vials)?6.

• ?Custom Synthesis?

  : Available in 

  ?1kg to 100kg batches?

   with tailored purity grades (98%-99.9%)?23.

?? ?Applications?

• ?Influenza Treatment?

  : Core intermediate for 

  ?Baloxavir Marboxil?

   production, used in single-dose oral flu therapies?13.

• ?Antiviral Research?

  : Supports R&D for 

  ?broad-spectrum RNA virus inhibitors?

   and pandemic preparedness?15.

• ?Combination Therapies?

  : Compatible with 

  ?protease inhibitors?

   and 

  ?neuraminidase inhibitors?

   for enhanced efficacy?36.

?? ?Quality Assurance?

• ?Documentation?

  : COA, MSDS, and stability reports aligned with 

  ?USP/EP standards?

  ?56.

• ?Traceability?

  : Lot-specific analytical data (NMR, HPLC, GC) for seamless API integration?23.